Cargando…

Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants

Krabbe disease is a severe, fatal neurodegenerative disorder caused by defects in the lysosomal enzyme galactocerebrosidase (GALC). The correct targeting of GALC to the lysosome is essential for the degradation of glycosphingolipids including the primary lipid component of myelin. Over 100 different...

Descripción completa

Detalles Bibliográficos
Autores principales: Spratley, Samantha J., Hill, Chris H., Viuff, Agnete H., Edgar, James R., Skjødt, Karsten, Deane, Janet E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons A/S 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949656/
https://www.ncbi.nlm.nih.gov/pubmed/27126738
http://dx.doi.org/10.1111/tra.12404
_version_ 1782443469596262400
author Spratley, Samantha J.
Hill, Chris H.
Viuff, Agnete H.
Edgar, James R.
Skjødt, Karsten
Deane, Janet E.
author_facet Spratley, Samantha J.
Hill, Chris H.
Viuff, Agnete H.
Edgar, James R.
Skjødt, Karsten
Deane, Janet E.
author_sort Spratley, Samantha J.
collection PubMed
description Krabbe disease is a severe, fatal neurodegenerative disorder caused by defects in the lysosomal enzyme galactocerebrosidase (GALC). The correct targeting of GALC to the lysosome is essential for the degradation of glycosphingolipids including the primary lipid component of myelin. Over 100 different mutations have been identified in GALC that cause Krabbe disease but the mechanisms by which they cause disease remain unclear. We have generated monoclonal antibodies against full‐length human GALC and used these to monitor the trafficking and processing of GALC variants in cell‐based assays and by immunofluorescence microscopy. Striking differences in the secretion, processing and endosomal targeting of GALC variants allows the classification of these into distinct categories. A subset of GALC variants are not secreted by cells, not proteolytically processed, and remain trapped in the ER; these are likely to cause disease due to protein misfolding and should be targeted for pharmacological chaperone therapies. Other GALC variants can be correctly secreted by cells and cause disease due to catalytic defects in the enzyme active site, inappropriate post‐translational modification or a potential inability to bind essential cofactors. The classification of disease pathogenesis presented here provides a molecular framework for appropriate targeting of future Krabbe disease therapies. [Image: see text]
format Online
Article
Text
id pubmed-4949656
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley & Sons A/S
record_format MEDLINE/PubMed
spelling pubmed-49496562016-07-28 Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants Spratley, Samantha J. Hill, Chris H. Viuff, Agnete H. Edgar, James R. Skjødt, Karsten Deane, Janet E. Traffic Original Articles Krabbe disease is a severe, fatal neurodegenerative disorder caused by defects in the lysosomal enzyme galactocerebrosidase (GALC). The correct targeting of GALC to the lysosome is essential for the degradation of glycosphingolipids including the primary lipid component of myelin. Over 100 different mutations have been identified in GALC that cause Krabbe disease but the mechanisms by which they cause disease remain unclear. We have generated monoclonal antibodies against full‐length human GALC and used these to monitor the trafficking and processing of GALC variants in cell‐based assays and by immunofluorescence microscopy. Striking differences in the secretion, processing and endosomal targeting of GALC variants allows the classification of these into distinct categories. A subset of GALC variants are not secreted by cells, not proteolytically processed, and remain trapped in the ER; these are likely to cause disease due to protein misfolding and should be targeted for pharmacological chaperone therapies. Other GALC variants can be correctly secreted by cells and cause disease due to catalytic defects in the enzyme active site, inappropriate post‐translational modification or a potential inability to bind essential cofactors. The classification of disease pathogenesis presented here provides a molecular framework for appropriate targeting of future Krabbe disease therapies. [Image: see text] John Wiley & Sons A/S 2016-05-30 2016-08 /pmc/articles/PMC4949656/ /pubmed/27126738 http://dx.doi.org/10.1111/tra.12404 Text en © 2016 The Authors. Traffic published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Spratley, Samantha J.
Hill, Chris H.
Viuff, Agnete H.
Edgar, James R.
Skjødt, Karsten
Deane, Janet E.
Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants
title Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants
title_full Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants
title_fullStr Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants
title_full_unstemmed Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants
title_short Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants
title_sort molecular mechanisms of disease pathogenesis differ in krabbe disease variants
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949656/
https://www.ncbi.nlm.nih.gov/pubmed/27126738
http://dx.doi.org/10.1111/tra.12404
work_keys_str_mv AT spratleysamanthaj molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants
AT hillchrish molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants
AT viuffagneteh molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants
AT edgarjamesr molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants
AT skjødtkarsten molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants
AT deanejanete molecularmechanismsofdiseasepathogenesisdifferinkrabbediseasevariants